KR102482597B1 - 감염 치료용 치료제 - Google Patents

감염 치료용 치료제 Download PDF

Info

Publication number
KR102482597B1
KR102482597B1 KR1020227003691A KR20227003691A KR102482597B1 KR 102482597 B1 KR102482597 B1 KR 102482597B1 KR 1020227003691 A KR1020227003691 A KR 1020227003691A KR 20227003691 A KR20227003691 A KR 20227003691A KR 102482597 B1 KR102482597 B1 KR 102482597B1
Authority
KR
South Korea
Prior art keywords
carrier
micro
donor
therapeutic agent
chemicals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227003691A
Other languages
English (en)
Korean (ko)
Other versions
KR20220021029A (ko
Inventor
아드리안 네빌 펠로우스
Original Assignee
아가 나노테크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아가 나노테크 리미티드 filed Critical 아가 나노테크 리미티드
Publication of KR20220021029A publication Critical patent/KR20220021029A/ko
Application granted granted Critical
Publication of KR102482597B1 publication Critical patent/KR102482597B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227003691A 2014-04-01 2015-03-24 감염 치료용 치료제 Active KR102482597B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1405874.7 2014-04-01
GBGB1405874.7A GB201405874D0 (en) 2014-04-01 2014-04-01 A therapeutic agent for use in the treatment of infections
GB1415063.5 2014-08-26
GBGB1415063.5A GB201415063D0 (en) 2014-04-01 2014-08-26 A therapeutic agent for use in the treatment of infections
KR1020167030614A KR102359855B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제
PCT/GB2015/000100 WO2015150722A1 (en) 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030614A Division KR102359855B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Publications (2)

Publication Number Publication Date
KR20220021029A KR20220021029A (ko) 2022-02-21
KR102482597B1 true KR102482597B1 (ko) 2022-12-29

Family

ID=50737835

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227003691A Active KR102482597B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제
KR1020167030614A Active KR102359855B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167030614A Active KR102359855B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Country Status (16)

Country Link
US (2) US9913805B2 (https=)
EP (2) EP3125874B1 (https=)
JP (1) JP6573286B2 (https=)
KR (2) KR102482597B1 (https=)
CN (1) CN106456557B (https=)
AU (1) AU2015242495B2 (https=)
CA (1) CA2943431C (https=)
DK (1) DK3125874T3 (https=)
ES (2) ES2953755T3 (https=)
GB (3) GB201405874D0 (https=)
IL (1) IL247969B (https=)
MX (1) MX2016012757A (https=)
NZ (1) NZ724298A (https=)
SG (2) SG10201801524PA (https=)
WO (1) WO2015150722A1 (https=)
ZA (1) ZA201606387B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551501B2 (en) 2012-02-17 2026-02-17 Wiab Water Innovation Ab Compositions and methods for treating biofilms without inducing antimicrobial resistance
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections
CN107281220B (zh) * 2016-03-31 2020-02-14 中国科学院上海硅酸盐研究所 一种介孔氧化硅基活性氧(ros)放疗增敏剂及其制备方法
CN106860032B (zh) * 2016-10-25 2021-04-09 咏达生医材料股份有限公司 一种气态皮肤供氧美白产品及其应用
US12605403B2 (en) 2016-12-22 2026-04-21 Wiab Water Innovation Ab Compositions and methods for treating transient biofilms
JP2019194162A (ja) * 2018-05-01 2019-11-07 ツァ ギャリー 肌の酸素供給による美白及び加熱機能を備えた通気性材料
CA3152075A1 (en) 2019-10-10 2021-04-15 Alpha Tau Medical Ltd. Wet preparation of radiotherapy sources
GB2592911B (en) * 2020-02-28 2023-06-28 Aga Nanotech Ltd A plasma-activatable wound dressing for treatment of infections
GB202005556D0 (en) 2020-04-16 2020-06-03 Aga Nanotech Ltd Covid face mask

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088498A1 (en) * 2004-10-27 2006-04-27 Truox, Inc. Anti-microbial composition using in-situ generation of an oxidizing agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908614A (en) 1995-08-15 1999-06-01 Montgomery; Robert Eric Peroxidase-activating oral compositions
EP1064910B1 (de) * 1999-07-02 2005-09-14 Cognis IP Management GmbH Mikrokapseln - IV
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
KR100342746B1 (ko) * 2000-06-27 2002-07-03 김찬화 인슐린의 방출제어제제 및 그 방법
GB0411304D0 (en) * 2004-05-21 2004-06-23 Fellows Adrian N An antimicrobial composition
EP1919507A2 (en) * 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
KR20070071225A (ko) * 2005-12-29 2007-07-04 애경산업(주) 치아 미백용 조성물
GB0711952D0 (en) * 2007-06-20 2007-08-01 King S College London Microspheres
US20110218140A1 (en) * 2008-02-25 2011-09-08 Gonsalves Kenneth E Biodegradable therapeutic nanoparticles containing an antimicrobial agent
EP2313122B1 (en) * 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US8969282B2 (en) * 2009-02-05 2015-03-03 American Sterilizer Company Low odor, hard surface sporicide
US8889161B2 (en) * 2009-04-27 2014-11-18 Premier Dental Products Company Microencapsulated compositions and methods for tissue mineralization
KR101136028B1 (ko) * 2009-04-27 2012-04-18 한양대학교 산학협력단 다공성 마이크로스피어의 제조방법
NZ600269A (en) * 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
US9187594B2 (en) * 2010-02-09 2015-11-17 The Regents Of The University Of Michigan Nano-fibrous microspheres and methods for making the same
HUE033386T2 (en) * 2010-07-09 2017-11-28 Innocore Tech B V Release of Biodegradable Phase Separated Segmented Multiblock Copolymers and Biologically Active Polypeptides
CN103221070B (zh) * 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088498A1 (en) * 2004-10-27 2006-04-27 Truox, Inc. Anti-microbial composition using in-situ generation of an oxidizing agent

Also Published As

Publication number Publication date
EP3125874A1 (en) 2017-02-08
NZ724298A (en) 2022-07-01
ZA201606387B (en) 2017-11-29
US20170079930A1 (en) 2017-03-23
MX2016012757A (es) 2017-04-27
CA2943431C (en) 2022-08-23
EP3848022B1 (en) 2023-06-07
CA2943431A1 (en) 2015-10-08
EP3848022A1 (en) 2021-07-14
AU2015242495B2 (en) 2020-04-30
GB2538923A (en) 2016-11-30
US20180207105A1 (en) 2018-07-26
DK3125874T3 (da) 2021-03-22
GB201405874D0 (en) 2014-05-14
EP3848022C0 (en) 2023-06-07
GB201415063D0 (en) 2014-10-08
IL247969B (en) 2018-12-31
EP3125874B1 (en) 2020-12-30
SG11201608093WA (en) 2016-10-28
GB2538923B (en) 2020-03-25
KR102359855B1 (ko) 2022-02-08
ES2855985T3 (es) 2021-09-27
GB201617053D0 (en) 2016-11-23
JP2017510648A (ja) 2017-04-13
CN106456557A (zh) 2017-02-22
KR20220021029A (ko) 2022-02-21
US9913805B2 (en) 2018-03-13
SG10201801524PA (en) 2018-04-27
US10933026B2 (en) 2021-03-02
AU2015242495A1 (en) 2016-10-06
KR20160144408A (ko) 2016-12-16
ES2953755T3 (es) 2023-11-15
JP6573286B2 (ja) 2019-09-11
WO2015150722A1 (en) 2015-10-08
CN106456557B (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
KR102482597B1 (ko) 감염 치료용 치료제
Li et al. Nano–bio interactions: biofilm‐targeted antibacterial nanomaterials
Wang et al. Tunable zeolitic imidazolate framework‐8 nanoparticles for biomedical applications
Li et al. Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo
Stewart et al. Drug self-assembly for synthesis of highly-loaded antimicrobial drug-silica particles
Huang et al. Silver-decorated polymeric micelles combined with curcumin for enhanced antibacterial activity
Xue et al. An exceptional broad-spectrum nanobiocide for multimodal and synergistic inactivation of drug-resistant bacteria
Shende et al. Polymeric nanodroplets: an emerging trend in gaseous delivery system
CN111012910A (zh) 一种纳米银结合光敏剂聚合物胶束及其制备方法与应用
Sofokleous et al. Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles
Kanth et al. Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers
Long et al. Improving the pharmacokinetics and tissue distribution of pyrinezolid by self-assembled polymeric micelles
HK40052395A (en) A therapeutic agent for use in the treatment of infections
HK1233167B (zh) 在感染的治疗中使用的治疗剂
Zewdu et al. Emerging mesoporous silica nanoparticle-mediated controlled and targeted drug delivery system: Present status and future prospects
CN114984212A (zh) 纳米杀菌材料、化合物、聚合物以及这些物质在制备纳米杀菌剂中的应用
HK1233167A1 (en) A therapeutic agent for use in the treatment of infections
Feng et al. Bacteria-responsive drug release platform for the local treatment of bacterial vaginosis
CN119345112B (zh) 一种载有热休克蛋白抑制剂的脂质体水凝胶及其制备与应用
Zhang et al. Polymeric nanoparticulate delivery vehicles of antimicrobials for biofilm eradication
Chen et al. Biofilm-microenvironment responsive hybrid micelle based on novel betaine derivative for enhanced delivery of honokiol against stubborn bacterial biofilms
Stewart Co-Assembled Drug-Silica Materials for Antimicrobial and Antidegradative Dental Applications
CN116617182A (zh) 阳离子聚合物脂质纳米颗粒的制备及其用途
JP2023516026A (ja) 活性化可能な創傷被覆材
BR102017018487A2 (pt) Formulação, processo de produção de nanocápsulas, processo de produção de microesferas e uso da formulação

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220203

Application number text: 1020167030614

Filing date: 20161101

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220216

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220502

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221226

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221227

End annual number: 3

Start annual number: 1

PG1601 Publication of registration